following a resubmission:
brodalumab (Kyntheum®) is accepted for restricted use within NHSScotland.
Indication under review: for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
SMC restriction: for patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.
Brodalumab was superior to placebo and to an alternative interleukin inhibitor at improving symptoms in adults with moderate to severe plaque psoriasis.
This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost- effectiveness of brodalumab. It is contingent upon the continuing availability of the Patient Access Scheme in NHSScotland or a list price that is equivalent or lower.
Download detailed advice278KB (PDF)
- Medicine name:
- brodalumab (Kyntheum)
- SMC ID:
- For the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy.
- Pharmaceutical company
- LEO Pharmaceuticals
- BNF chapter
- Submission type
- Date advice published:
- 07 May 2018